SmithKline Beecham
This article was originally published in The Tan Sheet
Executive Summary
Will consolidate majority of its U.K. R&D activities at a 40- acre site in Harlow, Essex that is adjacent to an existing SB R&D facility. The deal to buy the former British Petroleum maritime HQ site in Harlow means SB will reduce its U.K. R&D facilities from seven to three and provides the company with an opportunity to merge into one R&D site, if desired. SB is projecting "significant cost savings" from the move. Most non-lab groups will be moved to Harlow by the third quarter of 1994, SB said.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning